Metabolic syndrome and kidney disease;Síndrome metabólico y nefropatía

Nefrologia

Volumn 28, Issue SUPPL. 3, 2008, Pages 33-37

  Castelao, A Martínez ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cardiovascular risk; Chronic kidney disease; Metabolic syndrome

Indexed keywords

EID: 51349153298     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts and different goals. Endocrinol Metab Clin North Am 2004; 33: 283-303.
2. Grupo de trabajo de Resistencia a la insulina de la Sociedad Española de Diabetes (SED). Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes tipo 2. Med Clin (Bare), 2002; 119: 458-463.
3. Griera JL. Obesidad y síndrome metabólico. Rev Esp Obes 2005; Supl. 3: 36-54.
4. López de la Torre M. Algoritmo diagnóstico y terapéutico de la resistencia a la insulina. Guías de actuación clínica en la diabetes mellitus. Endocrinologí a y Nutrición 2006; 56-60.
5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
6. Matthewss D, Hosker J, Rudenski A, Taylor B, Teacher D, Turner R. Homoestasis model assessment insulin resistence and cell function from fasting plasma glucose and insulin concentration in man. Diabetología 1985; 28: 412-9.
7. Martínez Calatrava MJ, Martínez Larrad MT, Serrano Ríos M. Síndrome de resistencia a la insulina y metabólico: concepto, fisiopatología y epidemiología. Cardiov Risc Factors 2003; 12 (2): 89-95.
8. Hanley AJG, Wagenknecht LE, D'Agostino RBjr, Zimman B, Haffner SMN. Identification of subjects with insuoin resistance and betaecell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 2003; 52: 2740-2747.
9. Balkan B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 6: 442-443.
10. Grundy SM, Brewer HB, Cleman JI, Smith SC, Lenfant C for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung and Blod Institute/American Heart Asociation conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
11. Einhorn D, Reaven GMM, Gobin RH, Ford E, Ganda OP, Handelsman Y y cols. American College of Endocrinoloy position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-252.
12. International Diabetes Ferderation. The IDF Consensus World wide definition of the metabolic syndrome, Ap 14 2005. Disponible en www.idf.org
13. Ascaso JF, González-Santos P, Hernández-Mijares A, Mangas Rojas A, Masana Marín L, Millán Núñez-Cortés J, Pallardó LF, Pedro-Botte J, Pérez Jiménez F, Pintó X, Plaza I, Rubiés-Prat J, Zúñiga M. Diagnóstico del síndrome metabólico. Adecuación de los criterios diagnósticos en nuestro medio. Recomendaciones de foro HDL. Resumen ejecutivo. Rev Clin Esp 2006; (11): 576-582.
14. Aranceta J, Pérez C, Serra L, Vioque J, Tur JA, Mataix J y cols. Estudio DORICA: Dislipemia, Obesidad y Riesgo Cardiovascular. Obesidad y Riesgo Cardiovascular. En: Aranceta J, Foz M, Gil B, Jover E, Mantilla T, Millán J y cols, (editores). Editorial Panamericana, 2004: 125-126.
15. Merino-Ibarra E, Cenarro A, Martín P, García-Otín Al, Goicoechea J, Guallar A, Calvo L, Clveira F. Sensibilidad y especificidad de los criterios del síndrome metabólico para el diagnóstico de insulina-resistencia en la población española. Med Clin (Barcelona) 2007; 128 (5): 168-171.
16. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic sindrome and chronic kidney disease in US adults. Ann Inter Med 2004; 140: 167-174.
17. Ridker PM for JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low-density lipoprotein colesterol and elevated high-sensitivity C-reactive protein: rational and designe of the JUPITER trial. Circulation 2003; 108 (19): 2292-2293.
18. Lakka HM, Laaksonen DE, Niskanen LK, Kumpusalo E, Tuomilheto J y cols. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2016.
19. Kurella M, Io JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease in non diabetic adults. JASN 2005; 16 (7): 2134-2140.
20. Díaz R y Varea V. La Vanguardia, 25 noviembre 2006.
21. Reis EC, Kip KE, Marroquin OC, Kiesau M, Hipps L, Peters RE, Reis SE. Screening children to identity families at increased risk for cardiovascular disease. Pediatric 2006; 118 (6): e1789-1797.
22. Bakris G, Molitch M, Hewkin A, Kipnes M, Serafidis P, Fakouhi K, Bacher P, Sowers J, START investigators. Differences in glucose tolerance between fixed-doses antihypertensive drug combinations in people with metabolic syndrome. Diab Care 2006; 29 (12): 2592-2597.